首页> Cancer Chemotherapy and Pharmacology> Phase 1 and dose-finding study of patritumab (U3-1287), a human monoclonal antibody targeting HER3, in Japanese patients with advanced solid tumors.

Phase 1 and dose-finding study of patritumab (U3-1287), a human monoclonal antibody targeting HER3, in Japanese patients with advanced solid tumors.

导出原文传递

翻译打印收藏纠错

第一作者： Hiroshi Wakui

作者： Hiroshi Wakui ^[1] ; Noboru Yamamoto ; Shinji Nakamichi ; Yousuke Tamura ; Hiroshi Nokihara ; Yasuhide Yamada ; Tomohide Tamura

作者单位： Department of Thoracic Oncology, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-ku, Tokyo ^[1]

发布时间 2018-09-20

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Cancer Chemotherapy and Pharmacology

2014年73卷3期

511-516页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览0

点击下载本期目录封面

Cancer Chemotherapy and Pharmacology

2014年73卷3期

511-516页

检索历史清除

Phase 1 and dose-finding study of patritumab (U3-1287), a human monoclonal antibody targeting HER3, in Japanese patients with advanced solid tumors.

Cancer Chemotherapy and Pharmacology

相似文献

同项目论文

Cancer Chemotherapy and Pharmacology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Phase 1 and dose-finding study of patritumab (U3-1287), a human monoclonal antibody targeting HER3, in Japanese patients with advanced solid tumors.

Cancer Chemotherapy and Pharmacology

相似文献

同项目论文

Cancer Chemotherapy and Pharmacology

相关期刊

检索历史清除